[exclusive] the price of nitroglycerin has exceeded the previous government limit

Drug intelligence: Recently, the price of nitroglycerin has broken through the previous government price limit CDRC: the price of the drug "exceeds the limit" phenomenon 2019 or increases Since the beginning of 2019, the common drug nitroglycerin tablets used for angina treatment in Jiangsu, Liaoning and Shandong have been reported to be out of stock and up in price The price of 100 pieces of nitroglycerin tablets has generally increased to 40 yuan from 4.5 yuan in 2018 In this regard, the common explanation of drugstores and pharmaceutical factories is that the upstream suppliers shut down due to environmental problems, the shortage of raw materials, and some enterprises take the opportunity to bid up prices, resulting in the drug shortage and price increase According to the information of yaozhi.com, nitroglycerin tablet is a conventional and specific drug for the treatment of coronary heart disease and angina pectoris, which has a "just need" in the market After this price increase, the market price of the drug has approached or exceeded the retail price limit previously set Taking Guizhou Province as an example, according to qjh [2013] No 133, the highest retail price of nitroglycerin tablets per bottle is only 4.9 yuan Although drug prices exceed the limit, this situation happens occasionally, but in the past three years, the state has repeatedly issued policies to urge drug prices, occasionally it seems very abrupt In the view of Liu Xintian, Secretary General of China bulk commodity development research center, there is a certain inevitability in the emergence of drugs with nitroglycerin tablets as the representative He pointed out that first, the reform direction of the pharmaceutical system is to promote circulation, which is more market-oriented in nature, while drug price limit is more or less planned economy The change of supply and demand leads to the change of price, which is a basic market behavior There is no doubt that it is expected to restrict the change of drug price through price limit, which is often "more than enough" Secondly, although drug price reduction is a general trend, the reason why many drugs will be greatly reduced in recent years is that the policy and supervision gradually regulate the monopoly, kickback, layer by layer and other gray phenomena in the past drug circulation Fan, the ecological environment of drug circulation has been optimized, but the drug supply chain has not been completely upgraded Chemical industry is the upstream of drugs In recent years, there has been a great deal of regulation in the chemical industry Because of environmental protection problems, a considerable number of chemical plants have been shut down In 2018, nearly 30 chemical enterprises related to pharmaceutical intermediates were shut down in Zibo, Shandong Province alone It can be seen that the shortage and price increase of some upstream chemicals are the actual situation The supply of upstream raw materials and intermediates cannot be guaranteed or the price changes, which will inevitably affect the API or even the finished drugs, and this situation may be more frequent and common in 2019 Liu Xintian stressed that the structural problems of drug production caused by upstream production suspension cannot be ignored Drug processing and production is a systematic project A small raw material can affect a drug or even an industry If the national level does not pay attention to and solve in time, the more serious drug price "over limit" will still occur in 2019 Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.